# Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/SNDX/syndax-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update
Ticker: SNDX
Company: Syndax Pharmaceuticals
Source: Syndax Pharmaceuticals
Published: 2026-02-26 21:01 EST
Original Source URL: https://ir.syndax.com
## Summary

– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 –  – Revuforj ® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™ (axatilimab-csfr) net revenue of $56.0 million in 4Q25, a 22% increase vs 3Q25, and $151.6

## Article Body
– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 –  – Revuforj ® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™ (axatilimab-csfr) net revenue of $56.0 million in 4Q25, a 22% increase vs 3Q25, and $151.6
## Recent Company News
- 2026-06-04 11:00 EST — [Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes](https://biopharmsignal.com/news/SNDX/syndax-announces-private-placement-of-250-0-million-of-convertible-senior-notes) — Source: Syndax Pharmaceuticals
- 2026-06-02 20:01 EST — [Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data](https://biopharmsignal.com/news/SNDX/syndax-highlights-revuforjr-revumenib-data-presented-at-asco-2026-including-an-oral-presentation-of-post-transplant-data) — Source: Syndax Pharmaceuticals
- 2026-06-01 11:00 EST — [Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026](https://biopharmsignal.com/news/SNDX/syndax-to-host-randd-day-highlighting-its-late-stage-programs-and-early-stage-assets-on-july-14-2026) — Source: Syndax Pharmaceuticals
- 2026-05-21 21:01 EST — [Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data](https://biopharmsignal.com/news/SNDX/syndax-announces-four-revuforjr-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data) — Source: Syndax Pharmaceuticals
- 2026-05-20 11:00 EST — [Syndax Announces Participation in Upcoming Investor Conferences](https://biopharmsignal.com/news/SNDX/syndax-announces-participation-in-upcoming-investor-conferences) — Source: Syndax Pharmaceuticals
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)